Novo Nordisk A/S $NVO Holdings Raised by Sivik Global Healthcare LLC

Key Points

• Sivik Global Healthcare LLC increased its stake in Novo Nordisk A/S by 42.9% during the second quarter, now holding 100,000 shares worth approximately $6.9 million.
• Novo Nordisk reported earnings of $0.97 EPS for the last quarter, exceeding analyst expectations of $0.93.
• The company's stock has a price target range from $70.00 to an average of $77.50, with a consensus rating of "Moderate Buy" from analysts.

Sivik Global Healthcare LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 42.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,000 shares of the company's stock after buying an additional 30,000 shares during the quarter. Novo Nordisk A/S makes up about 1.9% of Sivik Global Healthcare LLC's holdings, making the stock its 14th biggest position. Sivik Global Healthcare LLC's holdings in Novo Nordisk A/S were worth $6,902,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares in the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth $27,000. Stone House Investment Management LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth $30,000. Disciplina Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock worth $33,000 after purchasing an additional 297 shares during the last quarter. Finally, Spirit of America Management Corp NY acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth $35,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $56.95 on Friday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $120.56. The firm's fifty day simple moving average is $55.44 and its 200 day simple moving average is $63.16. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $254.27 billion, a PE ratio of 15.64, a PEG ratio of 2.58 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The business had revenue of $11.69 billion for the quarter, compared to analyst estimates of $77.51 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

Analyst Upgrades and Downgrades

NVO has been the topic of several analyst reports. HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, October 1st. Barclays restated an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Monday, September 29th. Weiss Ratings restated a "hold (c-)" rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Finally, Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research note on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $77.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.